7-甲基咪唑并[1,2-A]砒啶 | 874-39-5

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 中文名称: 7-甲基咪唑并[1,2-A]砒啶
• 中文别名: 7-甲基咪唑并[1,2-A]吡啶；7-甲基咪唑并[1,2a]吡啶；7-甲基咪唑并[1,2a]吡啶盐酸盐
• 英文名称: 7-Methyl-imidazo[1,2-a]pyridine
• 英文别名: 7-Methyl-imidazo<1.2-a>pyridin；7-Methyl-imidazo(1,2-a)pyr；7-Methylimidazo[1,2-a]pyridine
• CAS: 874-39-5
• 化学式: C₈H₈N₂
• 分子量: 132.165
• InChiKey: IQDUNRGHZFBKLT-UHFFFAOYSA-N

物化性质

• 沸点：
  113 °C(Press: 0.7 Torr)
• 密度：
  1.11±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  17.3
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8℃

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 7-Methylimidazo[1,2-a]pyridine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 7-Methylimidazo[1,2-a]pyridine
CAS number: 874-39-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H8N2
Molecular weight: 132.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  7-甲基咪唑并[1,2-A]砒啶 在 18-冠醚-6 氢氧化钾 、 氧气 作用下， 以 乙二醇二甲醚 为溶剂， 70.0 ℃ 、1.03 MPa 条件下， 反应 96.0h， 生成 咪唑并[1,2-A]吡啶-7-羧酸
  参考文献：
  名称：

  Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease

  摘要：

  这项发明提供了I式化合物： 这些化合物可以是药用盐或组合物的形式，可以是纯对映体形式或混合物，对于治疗已知涉及α7的疾病或病症的药物非常有用。

  公开号：

  US20030236264A1
• 作为产物：
  描述：

  2-氨基-4-甲基吡啶 、 氯乙醛 在 碳酸氢钠 作用下， 以 乙醇 、 水 为溶剂， 反应 2.0h， 生成 7-甲基咪唑并[1,2-A]砒啶
  参考文献：
  名称：

  通过C–H酰化和酰化作用的Pd催化串联环化反应，用于多环支架的构建

  摘要：

  提出了通过C–H芳基化和酰化反应，用2-氯苯甲醛将Pd催化的咪唑并[1,2- a ]吡啶串联环化反应，以有效合成新型6 H-苯并[ b ]咪唑并[5,1,2] -德〕喹6人。直接酰化反应在没有引导基团的帮助下并且在作为清洁和游离末端氧化剂的空气存在下顺利进行。

  DOI：

  10.1021/acs.orglett.6b02571

文献信息

• SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME
  申请人：BlinkBio, Inc.

  公开号：US20170202970A1

  公开（公告）日：2017-07-20

  Described herein are silicon based conjugates capable of delivering one or more payload moieties to a target cell or tissue. Contemplated conjugates may include a silicon-heteroatom core, one or more optional catalytic moieties, a targeting moiety that permits accumulation of the conjugate within a target cell or tissue, one or more payload moieties (e.g., a therapeutic agent or imaging agent), and two or more non-interfering moieties covalently bound to the silicon-heteroatom core.

  本文描述了基于硅的共轭物，能够将一个或多个有效载荷基团传递到靶细胞或组织。考虑到的共轭物可能包括一个硅-杂原子核心，一个或多个可选的催化基团，一个定位基团，允许共轭物在靶细胞或组织内积累，一个或多个有效载荷基团（例如，治疗剂或成像剂），以及与硅-杂原子核心共价结合的两个或更多个不干扰基团。
• A Carbonylation Approach Toward Activation of C_sp2-H and C_sp3-H Bonds: Cu-Catalyzed Regioselective Cross Coupling of Imidazo[1,2-<i>a</i>]pyridines with Methyl Hetarenes
  作者：Sai Lei、Yingying Mai、Caijuan Yan、Jianwen Mao、Hua Cao

  DOI：10.1021/acs.orglett.6b01588

  日期：2016.8.5

  An efficient copper-catalyzed selective cross coupling of imidazo[1,2-a]pyridines with methyl hetarenes has been reported. This transformation opened a new route to synthesize the C-3 carbonyl imidazo[1,2-a]pyridine derivative, which is a common structural motif in natural products and pharmaceuticals. 18O-labeling experiments indicated that the oxygen source of products originated from O2.

  已经报道了咪唑并[1,2- a ]吡啶与甲基己烯的有效铜催化选择性交叉偶联。这种转变为合成C-3羰基咪唑并[1,2- a ]吡啶衍生物开辟了一条新途径，该衍生物是天然产物和药物中常见的结构基序。18 O-标记实验表明产物的氧源来自O 2。
• [EN] BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES BICYCLIQUES COMME INHIBITEURS DE LA PROTÉINE TYROSINE KINASE
  申请人：ASTEX THERAPEUTICS LTD

  公开号：WO2009047506A1

  公开（公告）日：2009-04-16

  The invention relates to new bicyclic heterocyclic derivative compounds of formula (I): wherein R1, A, X1, X2, X3, X4, X5 and R2 are as defined herein, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

  这项发明涉及公式（I）的新的双环杂环衍生物化合物，其中R1、A、X1、X2、X3、X4、X5和R2如本文所定义，以及包含该化合物的药物组合物，以及该化合物在治疗疾病（例如癌症）中的用途。
• Pd-catalyzed oxidative cross-coupling of imidazo[1,2-a]pyridine with arenes
  作者：Shaohua Wang、Wenjie Liu、Jinghe Cen、Jinqiang Liao、Jianping Huang、Haiying Zhan

  DOI：10.1016/j.tetlet.2014.01.069

  日期：2014.2

  A facile method for direct Pd(OAc)2-catalyzed oxidative cross-coupling of unactivated imidazo[1,2-a]pyridine with simple arenes has been developed. The reaction shows good reaction efficiency, high regioselectivity, and good functional-group compatibility. This approach provides a useful protocol for the preparation of imidazo[1,2-a]pyridine–arene structure of interest in biological and pharmaceutical

  已开发了一种简便的方法，用于未活化的咪唑并[1,2- a ]吡啶与简单的芳烃的直接Pd（OAc）2催化的氧化交叉偶联。该反应显示出良好的反应效率，高的区域选择性和良好的官能团相容性。该方法为生物和药物材料中感兴趣的咪唑并[1,2 - a ]吡啶-芳烃结构的制备提供了有用的方案。
• Synthesis and antimuscarinic properties of some N-substituted 5-(aminomethyl)-3,3-diphenyl-2(3H)-furanones
  作者：Carl Kaiser、Ciro J. Spagnuolo、Theodore C. Adams、Vicki H. Audia、Andrea C. Dupont、Holia Hatoum、Valerie C. Lowe、Judith C. Prosser、Bonnie L. Sturm、Lalita Noronha-Blob

  DOI：10.1021/jm00101a019

  日期：1992.11

  selective antimuscarinic drugs with potential utility in the treatment of urinary incontinence associated with bladder muscle instability, a series of N-substituted 5-(aminomethyl)-3,3-diphenyl-2(3H)-furanones, conformationally-constrained lactone relatives of benactyzine, was prepared. The compounds were examined in several paradigms that measure muscarinic (M1, M2, and M3) receptor antagonist activity

  在一项旨在开发新的选择性抗毒蕈碱药物的研究中，该药物在治疗与膀胱肌不稳相关的尿失禁中具有潜在的实用性，一系列N-取代的5-（氨基甲基）-3,3-二苯基-2（3H）-呋喃酮，制备了受构造约束的贝内替嗪的内酯亲戚。在衡量毒蕈碱（M1，M2和M3）受体拮抗剂活性的几种范例中检查了这些化合物。研究了在这些测试中显示出效力和/或选择性的系列成员中的一些成员对豚鼠膀胱收缩，瞳孔散大和唾液分泌的影响。这些研究表明，将氨基官能团并入咪唑或吡唑环中会产生一些新颖，有效和选择性的抗毒蕈碱剂。咪唑位置2的适当烷基取代显着影响毒蕈碱，特别是M3受体活性，并可能反映相互作用的互补位点。一些化合物在膀胱造影（CMG）模型中选择性降低了膀胱压力，而没有产生散瞳和唾液效应。在这些体内方案中，该系列几种化合物的单独作用和不同作用表明，毒蕈碱受体亚型可能与先前表征的分子克隆亚群相对应。在本文中，讨论了一系列取代内酯的构效关系

表征谱图